Meeting
2021 ASCO Annual Meeting
A phase Ib study of a PI3Kδ inhibitor Linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma.
Authors
Jie Jin
First Hospital Affiliated Zhe Jiang Medical University, Hangzou, China
Jie Jin , Hong Cen , Keshu Zhou , Xiaohong Xu , Fei Li , Tao Wu , Haiyan Yang , Zheng Wang , Zhiming Li , Lugui Qiu , Hanying Bao , Zusheng Xu , Yang Shu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04108325
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7531)
DOI
10.1200/JCO.2021.39.15_suppl.7531
Abstract #
7531
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.
First Author: Martin H. Dreyling
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel
Poster
2023 ASCO Annual Meeting
Reduction in Curie score in neuroblastoma patients treated with naxitamab.
First Author: Jaume Mora